ArthroCare $74M shareholder lawsuit settlement draws judicial approval; NinePoint Medical gains CE mark for new imaging system;

 @FierceMedDev: Only a few weeks left to submit your nominations for the 15 fiercest private device developers. Survey | Follow @FierceMedDev

> A U.S. District Court judge in Texas has approved ArthroCare's $74 million settlement in a shareholder lawsuit that alleged falsely inflated share prices. Story

> NinePoint Medical gained a CE mark to use its NVisionVLE imaging system to diagnose mucosa and submucosa diseases, following an earlier FDA 510(k) clearance. Plans call for launching the product commercially in 2013. Release

> InSite Medical Technologies has raised new funding. The Saratoga, CA company makes medical devices that deliver epidural anesthesia. Item

> Ortho Clinical Diagnostics has gained a CE mark for a new diagnostic blood test designed to measure levels of vitamin D2 and D3 in the blood. Story

> Beacon Endoscopic is pursuing a limited market launch of its BNX fine needle aspiration tech for use with endoscopic ultrasound and endoscopic bronchial ultrasound, following FDA clearance in 2010 and a CE mark in January. Release

Biotech News

 @FierceBiotech: Complete Genomics axes 55 staffers, hires financial adviser to aid in exploring "strategic alternatives." Story | Follow @FierceBiotech

 @JohnCFierce: Merck may be better dumping sarcomas and focusing on other tumor types in the clinic. | Follow @JohnCFierce

 @RyanMFierce: With the FDA shunning Merck's ridaforolimus bid, Ariad looks pretty smart for front-ending its licensing terms with Merck on the cancer drug. | Follow @RyanMFierce

> ASCO Highlights: Top stories from this year's meeting. Report

> Chinese scientist convicted of stealing Merck's experimental drugs. News

> Merck KGaA and Dr. Reddy's partner on a slate of antibody biosims. Story

> FDA hits trap door button on Merck's weak ridaforolimus bid. Article

Pharma News

 @FiercePharma: Is the whole morning-after contraceptive fight based on a misunderstanding about how they work?--NYTReport | Follow @FiercePharma

> Study finds Roche's Actemra bests Abbott's blockbuster Humira. News

> Geneva workers propose scaleback at Merck Serono HQ. Report

> U.K. pharma balks at value-based pricing ideas. More

Drug Delivery News

 @DamianFierce: Zogenix is moving forward with its DosePro drug delivery platform, filing an IND for a new anti-psychotic. More | Follow @DamianFierce

> FDA wants more info on pen delivery for Amylin's Bydureon. Story

> At ASCO, unique delivery makes TDM-1 a standout. Item

> Aptar buys injectable delivery company for $207M. News

> MIT: DNA origami could safely deliver RNAi treatment. Article

Biomarkers News

> DNA tracking responses to cancer treatment. More

> A blood test for schizophrenia? Item

> Parkinson's disease gene cluster marks early diagnosis. Story

> Teens' low-fiber diets expand bellies, disease risks. Article

And Finally... Amylin Pharmaceuticals says FDA officials want data regarding a pen-delivery device designed to be used with the company's recently-approved, long-acting diabetes drug Bydureon. Story

Suggested Articles

The FDA has cleared its first fully disposable duodenoscope, following years of reports of infections being transmitted between patients.

OR-focused AI provider Caresyntax has garnered $45.6 million in new funding and picked up a data analytics firm to broaden its footprint.

A study of Foundation Medicine’s FoundationOne liquid biopsy test found it was able to predict the risk that a person’s breast cancer would return.